Biomarker-guided optimization of transcutaneous vagal stimulation for atrial fibrillation

Active Project Grant Awarded Last action

Award ID
R01HL161008
Recipient
Awarding agency
Obligated
$5,339,465

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 96% complete
Funding
  • $4,587,041.00 Federal
  • $752,424.00 Non-federal
Place of performance
Oklahoma City, OK 73104, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Atrial fibrillation (AF) is the most common clinically significant arrhythmia and is associated with increased cardiovascular morbidity and mortality. Recent evidence suggests that the autonomic nervous system plays a central role in the pathogenesis of AF, especially in the early stages and several studies from our group and others have shown that autonomic modulation with vagus nerve stimulation (VNS) can suppress AF in experimental models. We have exciting preliminary data from our recently completed randomized clinical trial showing that in ambulatory patients with paroxysmal AF, chronic, intermittent transcutaneous VNS (tvns) over 6 months resulted in a significant decrease in AF burden compared to sham stimulation. However, the response to tvns was variable among individual patients, highlighting the notion that while tvns is an emerging, promising modality for AF, the dosing and/or patient selection have to be optimized. Therefore, there is an urgent need to develop biomarkers that could 1) determine the optimal dosing regimen and 2) select the ideal candidates for tvns therapy, and thus optimally guide AF management. Our proposed studies will test the overall hypothesis that the effects of tvns on autonomic tone and atrial substrate can be used to guide and optimize therapy. Importantly, we have recently shown that p-wave alternans (PWA), a subtle beat-to-beat variation in the morphology of the p-wave, diminished in the active, compared to the sham group over a 6-month period and the decrease correlated with AF burden reduction. Therefore, we hypothesize that PWA is a useful tool for guiding tvns therapy for AF. We have also recently shown that the decrease in AF burden correlated with serum levels of neuropeptide y (NPY), a surrogate marker of sympathetic activity. Therefore, our proposed studies will test the hypothesis that assessment of subtle beat-to-beat variations in the p-wave morphology of the electrocardiogram (ECG) and serum levels of NPY can be used to first, determine the optimal parameters and second, guide tvns treatment. Our specific aims are: 1. To determine the effects of tvns on autonomic tone, atrial substrate and neuromodulators in patients with paroxysmal AF. 2. To investigate the chronic effects of optimal tvns on AF burden in patients with paroxysmal AF over a 6-month period, compared with sham stimulation and 3. To identify physiological and biochemical markers of response to chronic tvns. We anticipate that the results of these studies will first, provide insights into the effects of tvns on autonomic tone, AF substrate and neuromodulators, and second, permit optimization of tvns using PWA, NPY and metabolomic biomarkers to reduce AF burden of afflicted patients. By introducing an optimized tvns treatment protocol, results from our proposed studies have the potential to overturn the current scientific paradigm for treatment of AF, and thus, lead to major improvements in health care delivery. Because of the increasing number of patients with AF and the poor success and potential side effects of the available treatment options, an alternative approach such as tvns has the potential to impact clinical practice and improve outcomes for these patients.

Transactions

Action Federal Non-federal Date
Amendment $379,891 $0
Amendment $379,891 $0
Amendment $379,891 $0
Amendment $379,983 $0
Amendment $379,983 $0
Amendment $39,102 $0
Amendment $39,102 $0
Amendment $351,926 $0
Amendment $351,926 $351,926
Amendment $351,926 $0
Amendment $351,926 $0
Amendment $400,498 $0
Amendment $400,498 $400,498
Original award $400,498 $0
Show all 14

Subawards

Subrecipient Amount Awarded
The Broad Institute, Inc. PI will be responsible for all metabolite profiling activities conducted at the Broad Institute. 220 biological samples will be analyzed in total over the grant… $25,348
The General Hospital Corporation Dr. Antonis Armoundas will be in charge of the computer dedicated to data collection and analysis. We will use a previously described algorithm that has been… $190,628
The Broad Institute, Inc. Dr. Clary Clish serves as a PI and Senior Director of the Metabolomics Platform at the Broad Institute. Over the grant period, the Metabolomics Platform will… $25,348
The General Hospital Corporation Dr. Antonis Armoundas serves as a PI at the Division of Cardiology at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical… $192,938
The Broad Institute, Inc. Dr. Clary Clish serves as a PI and Senior Director of the Metabolomics Platform at the Broad Institute. Over the grant period, the Metabolomics Platform will… $49,594
The General Hospital Corporation Dr. Antonis Armoundas serves as a PI at the Division of Cardiology at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical… $19,294

Quick answers

Who received award R01HL161008?

R01HL161008 was awarded to University Of Oklahoma by National Heart Lung and Blood Institute (National Institutes of Health) on January 15, 2022.

How much is award R01HL161008 worth?

$5,339,465 has been obligated on R01HL161008: $4,587,041 in federal funding and $752,424 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login